With Claimed Designated Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/452)
  • Patent number: 10752589
    Abstract: The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula (I).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: August 25, 2020
    Assignee: SPHAERA PHARMA PVT. LTD.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Somdutta Sen
  • Patent number: 10736872
    Abstract: A pharmaceutical composition in a physiological dose for a mammal is used for reducing vascular calcification caused due to statin consumption. The composition contains mixture 1 and statin. The mixture 1 contains combination of the Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine. The mixture 1 can be used as a stand-alone product with or without statin.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: August 11, 2020
    Inventor: Matthias W Rath
  • Patent number: 10709668
    Abstract: The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an active ingredient and a diluent.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: July 14, 2020
    Assignee: CONFLUENCE PHARMACEUTICALS, LLC
    Inventors: Steven L. Johns, Kenneth G. Payie, Badrinath R. Doniparthi, Shivaraj B. Munianjanappa
  • Patent number: 10695305
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 30, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & CO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Patent number: 10695367
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10688058
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 23, 2020
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 10682322
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: June 16, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & GO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 10682376
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: June 16, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10610543
    Abstract: The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 7, 2020
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10603286
    Abstract: An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: March 31, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Hugues Straub, Stefaan Jaak Vanquickenborne
  • Patent number: 10596122
    Abstract: Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 24, 2020
    Assignee: Medical Research Council
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodriguez Faria, Laetitia Pele, Rachel Hewitt, Emma Thomas-McKay
  • Patent number: 10588864
    Abstract: Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal pH but can dissolve at pH>6. The core of a particulate can further comprise an excipient such as a diluent, a binder, a disintegrant, a lubricant, a glidant or a combination thereof. Particulates can comprise pharmaceutical compounds for treating colonic diseases such as C. difficile infection, ulcerative colitis, colon cancer, and Crohn's disease.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 17, 2020
    Assignee: Gateway Pharmaceuticals LLC
    Inventor: Lianli Li
  • Patent number: 10555940
    Abstract: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: February 11, 2020
    Inventor: Robert I. Henkin
  • Patent number: 10525011
    Abstract: A dosage form article consisting of a hard capsule coated with a surface modifying coating wherein the coating is an aqueous composition comprising water and a muco-adhesive polymer selected from the group consisting of poly(acrylates), cellulose derivatives, hyaluronic acid, starch, poly(ethylene glycol), polysaccharides, collagen derivatives, and mixtures thereof, wherein the ratio of the muco-adhesive polymer to water is less than 0.15 by weight of the coating composition.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 7, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, Hugues Straub
  • Patent number: 10493032
    Abstract: The invention relates to a nutritional and medicinal oral composition for veterinary use, including a core of complete feed extrudate coated with at least one layer of fat. The layer of fat includes at least one medicinal agent which includes: (i) at least one preconditioned active principle in the form of a solution or a suspension of said active principle in an oily liquid, or (ii) at least one preconditioned active principle in the form of waxy granules.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 3, 2019
    Assignee: VIRBAC
    Inventors: Nicolas Brunel, Fanny Martins, Patricia Goisnard
  • Patent number: 10471148
    Abstract: This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 12, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Janice Cacace, Peter H. R. Persicaner, Thorsteinn Thorsteinsson, Frederick Sancilio, Julia Amadio, Brian Bernick
  • Patent number: 10420729
    Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 24, 2019
    Assignee: R.P. Scherer Technologies, LLC
    Inventor: Simone Wengner
  • Patent number: 10172803
    Abstract: A problem of the present disclosure is, in one embodiment, to create a hard capsule formulation that includes a pharmaceutical agent or the like whose components deteriorate upon contact with an acid, in which the pharmaceutical agent or the like does not deteriorate due to gastric acid penetrating into the outer shell of the hard capsule. A hard capsule formulation comprising a hard capsule with acid resistance, in which the hard capsule is not treated with enteric coating, and the hard capsule formulation comprises an agent to inhibit invasion of gastric fluid and a pharmaceutical agent in the hard capsule.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 8, 2019
    Assignee: Capsugel Belgium NV
    Inventor: Takahisa Takubo
  • Patent number: 10155041
    Abstract: The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine. In particular, it relates to diseases that are associated with bacterial invasion of the intestinal mucus, including, inflammatory bowel diseases, and infectious bacterial diseases. Therefore, the present invention provides agents, a pharmaceutical composition and a kit for treating said diseases. It further relates to a use and a method for treating invasive bacterial diseases of the large intestine.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 18, 2018
    Assignee: Universitaetsklinikum Heidelberg
    Inventor: Wolfgang Stremmel
  • Patent number: 10149895
    Abstract: Described herein is an association of at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive antihypertensive agent and at least one antifibrotic agent for the management of progressive renal diseases including chronic kidney diseases (CKD) in domestic carnivores. Specifically, the application describes veterinarian compositions comprising such an association and the use thereof for the treatment of CKD conditions.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 11, 2018
    Assignee: VIRBAC
    Inventors: Natalia Bernachon, Patricia Monginoux
  • Patent number: 10004691
    Abstract: Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. A multiple-unit type orally disintegrating tablet containing enteric-coated micro granules containing acetylsalicylic acid, enteric-coated micro granules containing a proton pump inhibitor, and an additive, wherein an enteric coating layer of the enteric-coated micro granules containing acetylsalicylic acid contains an aqueous enteric polymer base and a sustained-release base.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: June 26, 2018
    Assignee: Takeda Pharmaceuticals Company Limited
    Inventors: Tetsuya Kawano, Yumiko Ishii
  • Patent number: 9937231
    Abstract: The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 10, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Rudolph Emile Tanzi, Ana Griciuc
  • Patent number: 9925148
    Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 27, 2018
    Assignee: Capsugel Belgium NV
    Inventors: Hassan Benameur, Dominique Nicolas Cade, Sophie Schreiber
  • Patent number: 9901588
    Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 27, 2018
    Assignee: Nestlé Skin Health SA
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Patent number: 9867865
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 16, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 9839632
    Abstract: Methods and compositions for treating, preventing or managing central nervous system cancers are disclosed. The methods encompass the administration of 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione, also known as Pomalidomide. Furthermore, provided herein are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: December 12, 2017
    Assignee: Celgene Corporation
    Inventor: Han W. Tun
  • Patent number: 9814683
    Abstract: A shell-forming composition for a soft capsule comprising a non-gelatin component as the chief component, wherein the shell-forming composition is able to inhibit a decrease in physical strength (breaking strength) of the capsule when a phospholipid-containing oil with a phospholipid concentration of 20% or more by mass is used as the core of the capsule. The shell-forming composition for the soft capsule comprises (A) starch and/or dextrin, (B) a gelatinizer, (C) glycerin and (D) sorbitol, and the mass ratio of (C) glycerin:(D) sorbitol ranges from 100:30 to 100:120.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 14, 2017
    Assignee: R.P. SCHERER TECHNOLOGIES, LLC
    Inventors: Takuma Fujii, Toshikazu Okayama, Michihiro Kimata, Yoshiaki Hanayama, Miyako Takahashi
  • Patent number: 9795569
    Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 24, 2017
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
  • Patent number: 9789187
    Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 17, 2017
    Assignee: Cadila Pharmaceuticals Limited
    Inventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi
  • Patent number: 9782416
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: October 10, 2017
    Assignee: Essentialis, Inc.
    Inventor: Neil Madison Cowen
  • Patent number: 9745278
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: August 29, 2017
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Patent number: 9693966
    Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: July 4, 2017
    Assignee: Banner Life Sciences LLC
    Inventor: Nachiappan Chidambaram
  • Patent number: 9675587
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 9662393
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 30, 2017
    Assignee: ACURA PHARMACEUTICALS, INC.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 9649280
    Abstract: The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: May 16, 2017
    Assignee: Diurnal Limited
    Inventors: Hiep Huatan, Richard Ross, Martin Whitaker, Norbert Poellinger, Annette Grave
  • Patent number: 9642810
    Abstract: Disclosed herein are stable pharmaceutical dosage forms containing carbidopa, levodopa, and entacapone. The dosage forms are prepared by mixing carbidopa, levodopa, and entacapone and forming granules. In some embodiments the granules also include starch. Microcrystalline cellulose can be added as an extragranular excipient. The stable pharmaceutical dosage forms have a bioavailability that is substantially similar to a dosage form prepared by adding a substantial portion of carbidopa separately from levodopa and entacapone.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 9, 2017
    Assignee: Mylan Inc.
    Inventors: Sarat C Chattaraj, Kimberly S Moss
  • Patent number: 9642816
    Abstract: The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 ?m and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 9, 2017
    Assignee: Universidade de Santiago de Compostela
    Inventors: María José Alonso Fernández, Noemi Csaba, José Vicente González Aramundiz
  • Patent number: 9597339
    Abstract: In one embodiment, the present application discloses methods of treating diseases and disorders with sulfasalazine and pharmaceutical formulations of sulfasalazine where the bioavailability of the sulfasalazine is increased. In another embodiment, the present application also provides dosing regimens for treating neurodegenerative diseases and disorders with compositions comprising sulfasalazine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 21, 2017
    Assignee: GLIALOGIX, INC.
    Inventors: Thaddeus Cromwell Reeder, Mark Wade Moore, Douglas Alan Lorenz, David Keith Lyon
  • Patent number: 9597291
    Abstract: The present invention relates to an orally disintegrating tablet (ODT) containing asenapine maleate and to a process for preparing the ODT. In a first aspect, the present invention relates to an ODT containing asenapine maleate and low substituted hydroxypropylcellulose. In a second aspect, the present invention relates to an ODT containing crystalline asenapine maleate and the ODT is prepared using conventional tabletting techniques as direct compression and granulation. In a third aspect, the present invention relates to an ODT containing asenapine maleate and a carboxylic acid, and to the use of a carboxylic acid for enhancing storage stability of an asenapine maleate containing ODT.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 21, 2017
    Assignee: ALFRED E. TIEFENBACHER (GMBH & CO. KG)
    Inventors: Chaitanya Yogananda Gujjar, Bala Ramesha Chary Rallabandi, Pradip Shivraj Patwari, Ansgar Fitzner
  • Patent number: 9511026
    Abstract: A poorly soluble drug containing microsphere with improved bioavailability, an oral formulation comprising the same, and a method of preparing the same are provided, wherein the poorly soluble drug containing microsphere is a solid dispersion wherein the poorly soluble drug is dispersed in the water-soluble polymer carrier in a noncrystalline form by spray drying, thus increasing bioavailability of the poorly soluble drug.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: December 6, 2016
    Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Kyung-Hee Kim, Hyun-Ki Lee, Jun-Seok Hwang, Su-Jong Hwang, Chaul-Min Pai
  • Patent number: 9456992
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: October 4, 2016
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Patent number: 9433620
    Abstract: The present invention relates to pharmaceutical compositions of lurasidone or salts thereof. In particular, the invention relates to pharmaceutical compositions of lurasidone or salts thereof with one or more water-insoluble pharmaceutical excipients. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of schizophrenia, bipolar disorders or senile dementia.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: September 6, 2016
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Brij Khera, Aman Trehan, Pankaj Ramanbhai Patel
  • Patent number: 9408806
    Abstract: The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 9, 2016
    Assignee: Wockhardt Limited
    Inventors: Girish Kumar Jain, Ramakant Gundu, Rahul Dabre
  • Patent number: 9394318
    Abstract: Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: July 19, 2016
    Assignee: Cypress Pharmaceuticals, Inc.
    Inventor: Robert L. Lewis
  • Patent number: 9320796
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: April 26, 2016
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 9161884
    Abstract: A process for providing a predetermined quantity of a particulate material in which the particulate material is deposited on a defined area of a sticky surface of a substrate. The process is suitable for deposition of particulate drug material on a substrate such as a strip form substrate which can then be compacted to provide a delivery device for delivering the predetermined quantity of the particulate material. Such a delivery device, and an apparatus to perform the process, comprise further aspects of the invention.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: October 20, 2015
    Assignee: Glaxo Group Limited
    Inventors: Stephen Barlow, Howard Biddle, Roderick Haines, Keith Smith
  • Patent number: 9138430
    Abstract: The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the active ingredient (e.g., paroxetine) in the large intestine of an individual in need thereof. In one embodiment, the present invention provides a controlled release paroxetine composition comprising paroxetine or a pharmaceutically acceptable salt thereof, in a controlled release swallow pharmaceutical formulation, that upon administration, releases the paroxetine substantially in the large intestine. For example, the controlled release paroxetine formulation may be formulated to release greater than about 50% of the paroxetine in the large intestine.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: September 22, 2015
    Assignee: Mylan Specialty L.P.
    Inventors: Jason Neely, David J. Wargo, Boyong Li, Thomas D. Reynolds
  • Patent number: 9101627
    Abstract: Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: August 11, 2015
    Assignee: ISTITUTO LUSO FARMACO D'ITALIA S.P.A.
    Inventors: Carlo Alberto Maggi, Sandro Giuliani, Laura Quartara
  • Patent number: 9089534
    Abstract: An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: July 28, 2015
    Assignee: Galephar Pharmaceutical Research, Inc.
    Inventors: Francis Vanderbist, Cecile Servais, Philippe Baudier
  • Publication number: 20150147391
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder